A phase 3, open-label, randomized study to assess the efficacy and safety of Camizestrant (AZD9833), a next generation. Oral selective estrogen receptor degrader, versus standard endocrine therapy, as adjusted treatment for patients with ER+/HER2- early breast cancer and an intermediate -high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence or disease
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
An Open label, Multicenter, Phase 1b/2a Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the ATR inhibitor M1774 in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies.